Fig. 5
Synaptic protein levels after sulfadiazine treatment. a Comparison of cortical synaptosomes from untreated control mice (INF−), toxo-infected (INF+), toxo-infected mice treated with sulfadiazine (INF+ and Sulfa+), and control mice with sulfadiazine treatment (INF− and Sulfa+) via immunoblotting. Protein levels from all selected synaptic marker, EAAT2, GABAAα1, Shank3, and GluA2 were upregulated after treatment with sulfadiazine. Control staining with synaptosomes from untreated mice and mice treated with sulfadiazine showed no significant differences. b According blots to the graph from a, treatment for each blot is indicated below: Toxoplasma positive (INF+) or negative (INF−) tissue, as well as sulfadiazine treatment (Sulfa+) are labeled accordingly. (Control mice (CTRL) n = 8, infected mice (INF) n = 4, infected mice with sulfadiazine (INF + Sulfa) n = 4, and control mice with sulfadiazine treatment (CTRL + Sulfa) n = 4). Displayed results are mean values ± SEM. **p < 0.01, *p < 0.05